Combined modality therapy with TRAIL or agonistic death receptor antibodies
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined modality therapy with TRAIL or agonistic death receptor antibodies
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 11, Issue 5, Pages 431-449
Publisher
Informa UK Limited
Online
2011-03-03
DOI
10.4161/cbt.11.5.14671
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhancement of tumor-TRAIL susceptibility by modulation of autophagy
- (2014) Wen Hou et al. Autophagy
- Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells
- (2014) Stavroula Baritaki et al. JOURNAL OF IMMUNOLOGY
- Targeting the pro-death and pro-survival functions of autophagy as novel therapeutic strategies in cancer
- (2010) Kevin Dalby et al. Autophagy
- Autophagic degradation of active caspase-8
- (2010) Wen Hou et al. Autophagy
- Death Receptor Agonists as a Targeted Therapy for Cancer
- (2010) J. Wiezorek et al. CLINICAL CANCER RESEARCH
- TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors
- (2010) D. Stadel et al. CLINICAL CANCER RESEARCH
- Targeting cancer cells through autophagy for anticancer therapy
- (2010) Sandra Turcotte et al. CURRENT OPINION IN CELL BIOLOGY
- Interaction of Beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL-induced apoptosis
- (2010) Ting-Kuang Niu et al. FEBS LETTERS
- TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5
- (2010) Johannes Lemke et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Autophagy: cellular and molecular mechanisms
- (2010) Danielle Glick et al. JOURNAL OF PATHOLOGY
- Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo
- (2010) M. Nagane et al. NEURO-ONCOLOGY
- New insights into apoptosis signaling by Apo2L/TRAIL
- (2010) F Gonzalvez et al. ONCOGENE
- Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway
- (2009) Kuen-Feng Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
- (2009) T. A. Luster et al. MOLECULAR CANCER THERAPEUTICS
- A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes
- (2008) A. Yada et al. ANNALS OF ONCOLOGY
- Death receptor-4 (DR4) expression is regulated by transcription factor NF-κB in response to etoposide treatment
- (2008) Francisco José Mendoza et al. APOPTOSIS
- BH3 Mimetic ABT-737 Potentiates TRAIL-Mediated Apoptotic Signaling by Unsequestering Bim and Bak in Human Pancreatic Cancer Cells
- (2008) S. Huang et al. CANCER RESEARCH
- Targeting XIAP Bypasses Bcl-2-Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth In vitro and In vivo
- (2008) M. Vogler et al. CANCER RESEARCH
- A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis
- (2008) L Weinmann et al. CELL DEATH AND DIFFERENTIATION
- Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival
- (2008) H. Jin et al. CLINICAL CANCER RESEARCH
- Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11
- (2008) P. G. Oliver et al. CLINICAL CANCER RESEARCH
- Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
- (2008) Simone Fulda CURRENT CANCER DRUG TARGETS
- Enhancement of Glioma Radiotherapy and Chemotherapy Response With Targeted Antibody Therapy Against Death Receptor 5
- (2008) John B. Fiveash et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Involvement of Protective Autophagy in TRAIL Resistance of Apoptosis-defective Tumor Cells
- (2008) Jie Han et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis
- (2008) Jin H. Song et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- To kill a tumor cell: the potential of proapoptotic receptor agonists
- (2008) Avi Ashkenazi et al. JOURNAL OF CLINICAL INVESTIGATION
- X Irradiation Combined with TNF α-related Apoptosis-inducing Ligand (TRAIL) Reduces Hypoxic Regions of Human Gastric Adenocarcinoma Xenografts in SCID Mice
- (2008) Momoko TAKAHASHI et al. JOURNAL OF RADIATION RESEARCH
- Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody
- (2008) A. Shanker et al. JNCI-Journal of the National Cancer Institute
- Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
- (2008) F. Anthony Greco et al. LUNG CANCER
- 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis
- (2008) Markus David Siegelin et al. NEUROBIOLOGY OF DISEASE
- Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1
- (2008) Sara Huerta-Yepez et al. NITRIC OXIDE-BIOLOGY AND CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now